| human | Q5 |
| P496 | ORCID iD | 0000-0003-0932-9104 |
| P69 | educated at | University of Helsinki | Q28695 |
| P108 | employer | University of Oulu | Q1357517 |
| P734 | family name | Winqvist | Q46044561 |
| Winqvist | Q46044561 | ||
| Winqvist | Q46044561 | ||
| P735 | given name | Robert | Q4927937 |
| Robert | Q4927937 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q69924476 | A new RFLP with StuI and probe cX55.7 (DXS105) and its usefulness in carrier analysis of fragile X syndrome |
| Q72427562 | A point mutation in the putative TATA box, detected in nondiseased individuals and patients with hereditary breast cancer, decreases promoter activity of the 17 beta-hydroxysteroid dehydrogenase type 1 gene 2 (EDH17B2) in vitro |
| Q55043120 | A recurrent mutation in PALB2 in Finnish cancer families. |
| Q43074862 | ATM mutations in Finnish breast cancer patients |
| Q28214329 | Analysis of 11q21-24 loss of heterozygosity candidate target genes in breast cancer: indications of TSLC1 promoter hypermethylation |
| Q33337514 | Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families |
| Q41465811 | Application of fine-needle aspiration to the demonstration of ERBB2 and MYC expression by in situ hybridization in breast carcinoma |
| Q35134888 | Assessment of targeted and non-targeted responses in cells deficient in ATM function following exposure to low and high dose X-rays |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q54398596 | Association of common ATM polymorphism with bilateral breast cancer. |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q37406868 | Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions |
| Q57305977 | Breast-Cancer Risk in Families With Mutations in PALB2 |
| Q34148873 | Breast-cancer risk in families with mutations in PALB2 |
| Q33677756 | Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility |
| Q24301364 | Characterization and expression of the human WNT4; lack of associated germline mutations in high--to moderate--risk breast and ovarian cancer |
| Q57232824 | Chromosome 7 long arm deletion in myeloid disorders: a narrow breakpoint region in 7q22 defined by molecular mapping |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q62772229 | Erratum: Genome-wide scanning for linkage in Finnish breast cancer families |
| Q36617728 | European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium |
| Q34938728 | Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families |
| Q51773668 | Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer. |
| Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
| Q24538977 | Evidence of founder mutations in Finnish BRCA1 and BRCA2 families |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q52934654 | Exclusion of large deletions and other rearrangements in BRCA1 and BRCA2 in Finnish breast and ovarian cancer families. |
| Q37394076 | FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome |
| Q42683589 | FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q37217527 | Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q57305889 | Finnish Fanconi anemia mutations and hereditary predisposition to breast and prostate cancer |
| Q114182808 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q57305903 | Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q57274804 | Genome-wide scanning for linkage in Finnish breast cancer families |
| Q34173446 | Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families |
| Q59566871 | Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility |
| Q38823212 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk |
| Q36622192 | Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites |
| Q64388571 | Germline alterations in the 53BP1 gene in breast and ovarian cancer families |
| Q114182677 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis |
| Q54473072 | Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations. |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q37305285 | Heterozygous mutations in PALB2 cause DNA replication and damage response defects |
| Q41483086 | Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q71739620 | Improved carrier testing for multiple endocrine neoplasia, type 1, using new microsatellite-type DNA markers |
| Q28506416 | Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice |
| Q53341737 | Increasing oxidative damage and loss of mismatch repair enzymes during breast carcinogenesis. |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q24305387 | Intrachromosomal rearrangements fusing L-myc and rlf in small-cell lung cancer |
| Q41581759 | KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q52472252 | Linkage disequilibrium detected between dystrophia myotonica and APOC2 locus in the Finnish population. |
| Q43009109 | Long-term observational follow-up study of breast cancer diagnosed in women ≤40 years old. |
| Q59539067 | Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study |
| Q73263784 | Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables |
| Q58769239 | Machine learning identifies interacting genetic variants contributing to breast cancer risk: A case study in Finnish cases and controls |
| Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q57232775 | Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q73038076 | Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer |
| Q43199043 | Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers |
| Q33520087 | Mutation analysis of the AATF gene in breast cancer families |
| Q24810690 | Mutation analysis of the ATR gene in breast and ovarian cancer families |
| Q36623420 | Mutation analysis of the CHK2 gene in families with hereditary breast cancer |
| Q35446729 | Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer |
| Q33824592 | Mutation screening of the MERIT40 gene encoding a novel BRCA1 and RAP80 interacting protein in breast cancer families |
| Q33966572 | Mutation screening of the RNF8, UBC13 and MMS2 genes in Northern Finnish breast cancer families |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q28207250 | No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families |
| Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
| Q36927115 | Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
| Q36184231 | PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. |
| Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
| Q35741630 | Pathology of ovarian cancers in BRCA1 and BRCA2 carriers |
| Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
| Q27851443 | Penetrance analysis of the PALB2 c.1592delT founder mutation |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q34425705 | RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q34318239 | Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network |
| Q48229615 | Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer |
| Q34695260 | Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
| Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
| Q52565103 | Screening for RAD51 and BRCA2 BRC repeat mutations in breast and ovarian cancer families. |
| Q54423137 | Screening for large genomic rearrangements of the BRIP1 and CHK1 genes in Finnish breast cancer families. |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q33369984 | Somatic mutation analysis of MYH11 in breast and prostate cancer |
| Q35906993 | Targeted Next-Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility |
| Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
| Q36917100 | The UGT1A6_19_GG genotype is a breast cancer risk factor |
| Q27824864 | The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer |
| Q35004850 | The gene for 17 beta-hydroxysteroid dehydrogenase maps to human chromosome 17, bands q12-q21, and shows an RFLP with ScaI. |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q67484388 | Unstable DNA may be responsible for the incomplete penetrance of the myotonic dystrophy phenotype |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
Search more.